Note to users. If you're seeing this message, it means that your browser cannot find this page's style/presentation instructions -- or possibly that you are using a browser that does not support current Web standards. Find out more about why this message is appearing, and what you can do to make your experience of our site the best it can be.

Science 17 November 1995:
Vol. 270. no. 5239, pp. 1197 - 1199
DOI: 10.1126/science.270.5239.1197
Prev | Table of Contents | Next

Reports

Prevention of SIV Infection in Macaques by (R)-9-(2-Phosphonylmethoxypropyl)adenine

Che-Chung Tsai (1),  Kathryn E. Follis,  Alexander Sabo,  Thomas W. Beck,  Richard F. Grant,  Norbert Bischofberger,  Raoul E. Benveniste,  Roberta Black

The efficacy of pre- and postexposure treatment with the antiviral compound (R)-9-(2-phosphonylmethoxypropyl)adenine (PMPA) was tested against simian immunodeficiency virus (SIV) in macaques as a model for human immunodeficiency virus (HIV). PMPA was administered subcutaneously once daily beginning either 48 hours before, 4 hours after, or 24 hours after virus inoculation. Treatment continued for 4 weeks and the virologic, immunologic, and clinical status of the macaques was monitored for up to 56 weeks. PMPA prevented SIV infection in all macaques without toxicity, whereas all control macaques became infected. These results suggest a potential role for PMPA prophylaxis against early HIV infection in cases of known exposure.


C.-C. Tsai, K. E. Follis, A. Sabo, T. W. Beck, R. F. Grant, University of Washington Regional Primate Research Center, Seattle, WA 98195, USA.
N. Bischofberger, Gilead Sciences, Foster City, CA 94404, USA.
R. E. Benveniste, National Cancer Institute, Frederick, MD 21701, USA.
R. Black, Division of AIDS, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20852, USA.
(1) To whom correspondence should be addressed.


THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES:
Postexposure Prophylaxis for HIV Infection.
R. J. Landovitz and J. S. Currier (2009)
N. Engl. J. Med. 361, 1768-1775
   Full Text »    PDF »
HIV prone occupational exposures: epidemiology and factors associated with initiation of post-exposure prophylaxis.
D Zenner, S Tomkins, A Charlett, K Wellings, and F Ncube (2009)
J Epidemiol Community Health 63, 373-378
   Abstract »    Full Text »    PDF »
A macaque model of HIV-1 infection.
T. Hatziioannou, Z. Ambrose, N. P. Y. Chung, M. Piatak Jr., F. Yuan, C. M. Trubey, V. Coalter, R. Kiser, D. Schneider, J. Smedley, et al. (2009)
PNAS 106, 4425-4429
   Abstract »    Full Text »    PDF »
Evaluation and Management of the Infant Exposed to HIV-1 in the United States.
P. L. Havens, L. M. Mofenson, and and the Committee on Pediatric AIDS (2009)
Pediatrics 123, 175-187
   Abstract »    Full Text »    PDF »
Chronic Administration of Tenofovir to Rhesus Macaques from Infancy through Adulthood and Pregnancy: Summary of Pharmacokinetics and Biological and Virological Effects.
K. K. A. Van Rompay, L. Durand-Gasselin, L. L. Brignolo, A. S. Ray, K. Abel, T. Cihlar, A. Spinner, C. Jerome, J. Moore, B. P. Kearney, et al. (2008)
Antimicrob. Agents Chemother. 52, 3144-3160
   Abstract »    Full Text »    PDF »
Comparative Evaluation of Virus Transmission Inhibition by Dual-Acting Pyrimidinedione Microbicides Using the Microbicide Transmission and Sterilization Assay.
K. M. Watson, C. E. Buckheit, and R. W. Buckheit Jr. (2008)
Antimicrob. Agents Chemother. 52, 2787-2796
   Abstract »    Full Text »    PDF »
Significant Virus Replication in Langerhans Cells following Application of HIV to Abraded Skin: Relevance to Occupational Transmission of HIV.
T. Kawamura, Y. Koyanagi, Y. Nakamura, Y. Ogawa, A. Yamashita, T. Iwamoto, M. Ito, A. Blauvelt, and S. Shimada (2008)
J. Immunol. 180, 3297-3304
   Abstract »    Full Text »    PDF »
Occupational exposure to HIV and the use of post-exposure prophylaxis.
E. Hamlyn and P. Easterbrook (2007)
Occup. Med. 57, 329-336
   Abstract »    Full Text »    PDF »
Narrative Review: Antiretroviral Therapy to Prevent the Sexual Transmission of HIV-1.
M. S. Cohen, C. Gay, A. D.M. Kashuba, S. Blower, and L. Paxton (2007)
Ann Intern Med 146, 591-601
   Abstract »    Full Text »    PDF »
Preexposure prophylaxis for HIV: unproven promise and potential pitfalls..
A. Y. Liu, R. M. Grant, and S. P. Buchbinder (2006)
JAMA 296, 863-865
   Full Text »    PDF »
Preventing HIV infection.
R. Jones, B. Gazzard, and Y. Halima (2005)
BMJ 331, 1285-1286
   Full Text »    PDF »
Tenofovir Disoproxil Fumarate and an Optimized Background Regimen of Antiretroviral Agents as Salvage Therapy for Pediatric HIV Infection.
R. Hazra, R. I. Gafni, F. Maldarelli, F. M. Balis, A. N. Tullio, E. DeCarlo, C. J. Worrell, S. M. Steinberg, J. Flaherty, K. Yale, et al. (2005)
Pediatrics 116, e846-e854
   Abstract »    Full Text »    PDF »
Prophylaxis of HIV infection.
A. S. Omrani and A. Freedman (2005)
Br. Med. Bull. 73-74, 93-105
   Abstract »    Full Text »    PDF »
Suppression of Virus Load by Highly Active Antiretroviral Therapy in Rhesus Macaques Infected with a Recombinant Simian Immunodeficiency Virus Containing Reverse Transcriptase from Human Immunodeficiency Virus Type 1.
T. W. North, K. K. A. Van Rompay, J. Higgins, T. B. Matthews, D. A. Wadford, N. C. Pedersen, and R. F. Schinazi (2005)
J. Virol. 79, 7349-7354
   Abstract »    Full Text »    PDF »
Evaluation and Treatment of the Human Immunodeficiency Virus-1--Exposed Infant.
S. M. King, Committee on Pediatric AIDS, and Canadian Paediatric Society, Infectious Diseases a (2004)
Pediatrics 114, 497-505
   Abstract »    Full Text »    PDF »
CD8+-Cell-Mediated Suppression of Virulent Simian Immunodeficiency Virus during Tenofovir Treatment.
K. K. A. Van Rompay, R. P. Singh, B. Pahar, D. L. Sodora, C. Wingfield, J. R. Lawson, M. L. Marthas, and N. Bischofberger (2004)
J. Virol. 78, 5324-5337
   Abstract »    Full Text »    PDF »
Single-Dose and Steady-State Pharmacokinetics of Tenofovir Disoproxil Fumarate in Human Immunodeficiency Virus-Infected Children.
R. Hazra, F. M. Balis, A. N. Tullio, E. DeCarlo, C. J. Worrell, S. M. Steinberg, J. F. Flaherty, K. Yale, M. Poblenz, B. P. Kearney, et al. (2004)
Antimicrob. Agents Chemother. 48, 124-129
   Abstract »    Full Text »    PDF »
Tenofovir Resistance and Resensitization.
K. Wolf, H. Walter, N. Beerenwinkel, W. Keulen, R. Kaiser, D. Hoffmann, T. Lengauer, J. Selbig, A.-M. Vandamme, K. Korn, et al. (2003)
Antimicrob. Agents Chemother. 47, 3478-3484
   Abstract »    Full Text »    PDF »
Early Control of Highly Pathogenic Simian Immunodeficiency Virus/Human Immunodeficiency Virus Chimeric Virus Infections in Rhesus Monkeys Usually Results in Long-Lasting Asymptomatic Clinical Outcomes.
T. Igarashi, Y. Endo, Y. Nishimura, C. Buckler, R. Sadjadpour, O. K. Donau, M.-J. Dumaurier, R. J. Plishka, A. Buckler-White, and M. A. Martin (2003)
J. Virol. 77, 10829-10840
   Abstract »    Full Text »    PDF »
Clinical Potential of the Acyclic Nucleoside Phosphonates Cidofovir, Adefovir, and Tenofovir in Treatment of DNA Virus and Retrovirus Infections.
E. De Clercq (2003)
Clin. Microbiol. Rev. 16, 569-596
   Abstract »    Full Text »    PDF »
Tenofovir Disoproxil Fumarate in Nucleoside-Resistant HIV-1 Infection: A Randomized Trial.
K. Squires, A. L. Pozniak, G. Pierone Jr., C. R. Steinhart, D. Berger, N. C. Bellos, S. L. Becker, M. Wulfsohn, M. D. Miller, J. J. Toole, et al. (2003)
Ann Intern Med 139, 313-320
   Abstract »    Full Text »    PDF »
Pre-Exposure Chemoprophylaxis (PREP) as an HIV Prevention Strategy.
M. Youle and M. A. Wainberg (2003)
J Int Assoc Physicians AIDS Care (Chic Ill) 2, 102-105
   Abstract »    PDF »
Occupational Exposure to HIV in Health Care Settings.
J. L. Gerberding (2003)
N. Engl. J. Med. 348, 826-833
   Full Text »    PDF »
Effect of Humoral Immune Responses on Controlling Viremia during Primary Infection of Rhesus Monkeys with Simian Immunodeficiency Virus.
J. E. Schmitz, M. J. Kuroda, S. Santra, M. A. Simon, M. A. Lifton, W. Lin, R. Khunkhun, M. Piatak, J. D. Lifson, G. Grosschupff, et al. (2003)
J. Virol. 77, 2165-2173
   Abstract »    Full Text »    PDF »
Reversion of the M184V Mutation in Simian Immunodeficiency Virus Reverse Transcriptase Is Selected by Tenofovir, Even in the Presence of Lamivudine.
J. P. Murry, J. Higgins, T. B. Matthews, V. Y. Huang, K. K. A. Van Rompay, N. C. Pedersen, and T. W. North (2003)
J. Virol. 77, 1120-1130
   Abstract »    Full Text »    PDF »
Vaccination of Macaques with Long-Standing SIVmac251 Infection Lowers the Viral Set Point After Cessation of Antiretroviral Therapy.
E. Tryniszewska, J. Nacsa, M. G. Lewis, P. Silvera, D. Montefiori, D. Venzon, Z. Hel, R. W. Parks, M. Moniuszko, J. Tartaglia, et al. (2002)
J. Immunol. 169, 5347-5357
   Abstract »    Full Text »    PDF »
Phenotypic Susceptibilities to Tenofovir in a Large Panel of Clinically Derived Human Immunodeficiency Virus Type 1 Isolates.
P. R. Harrigan, M. D. Miller, P. McKenna, Z. L. Brumme, and B. A. Larder (2002)
Antimicrob. Agents Chemother. 46, 1067-1072
   Abstract »    Full Text »    PDF »
Animal studies and HIV research.
R. Greek, P. Pound, and N. L Haigwood (2002)
BMJ 324, 236
   Full Text »
Adoptive transfer of simian immunodeficiency virus (SIV) naive autologous CD4+ cells to macaques chronically infected with SIV is sufficient to induce long-term nonprogressor status.
F. Villinger, G. T. Brice, A. E. Mayne, P. Bostik, K. Mori, C. H. June, and A. A. Ansari (2002)
Blood 99, 590-599
   Abstract »    Full Text »    PDF »
Activation by 9-(R)-[2-(Phosphonomethoxy)Propyl]Adenine of Chemokine (RANTES, Macrophage Inflammatory Protein 1alpha ) and Cytokine (Tumor Necrosis Factor Alpha, Interleukin-10 [IL-10], IL-1beta ) Production.
Z. Zidek, D. Frankova, and A. Holy (2001)
Antimicrob. Agents Chemother. 45, 3381-3386
   Abstract »    Full Text »    PDF »
Role of CD8+ Lymphocytes in Control of Simian Immunodeficiency Virus Infection and Resistance to Rechallenge after Transient Early Antiretroviral Treatment.
J. D. Lifson, J. L. Rossio, M. Piatak Jr., T. Parks, L. Li, R. Kiser, V. Coalter, B. Fisher, B. M. Flynn, S. Czajak, et al. (2001)
J. Virol. 75, 10187-10199
   Abstract »    Full Text »    PDF »
Phase I/II Trial of the Pharmacokinetics, Safety, and Antiretroviral Activity of Tenofovir Disoproxil Fumarate in Human Immunodeficiency Virus-Infected Adults.
P. Barditch-Crovo, S. G. Deeks, A. Collier, S. Safrin, D. F. Coakley, M. Miller, B. P. Kearney, R. L. Coleman, P. D. Lamy, J. O. Kahn, et al. (2001)
Antimicrob. Agents Chemother. 45, 2733-2739
   Abstract »    Full Text »    PDF »
Antiretroviral Agents Restore Mycobacterium-Specific T-Cell Immune Responses and Facilitate Controlling a Fatal Tuberculosis-Like Disease in Macaques Coinfected with Simian Immunodeficiency Virus and Mycobacterium bovis BCG.
Y. Shen, L. Shen, P. Sehgal, D. Zhou, M. Simon, M. Miller, E. A. Enimi, B. Henckler, L. Chalifoux, N. Sehgal, et al. (2001)
J. Virol. 75, 8690-8696
   Abstract »    Full Text »    PDF »
Human Immunodeficiency Virus Postexposure Prophylaxis for Adolescents and Children.
R. C. Merchant and R. Keshavarz (2001)
Pediatrics 108 , e38
   Abstract »    Full Text »    PDF »
Prophylaxis Against Possible Human Immunodeficiency Virus Exposure After Nonoccupational Needlestick Injuries or Sexual Assaults in Children and Adolescents.
F. E. Babl, E. R. Cooper, B. Kastner, and S. Kharasch (2001)
Arch Pediatr Adolesc Med 155, 680-682
   Abstract »    Full Text »    PDF »
Macrophage are the principal reservoir and sustain high virus loads in rhesus macaques after the depletion of CD4+ T cells by a highly pathogenic simian immunodeficiency virus/HIV type 1 chimera (SHIV): Implications for HIV-1 infections of humans.
T. Igarashi, C. R. Brown, Y. Endo, A. Buckler-White, R. Plishka, N. Bischofberger, V. Hirsch, and M. A. Martin (2000)
PNAS
   Abstract »    Full Text »
Control of SIV Rebound Through Structured Treatment Interruptions During Early Infection.
F. Lori, M. G. Lewis, J. Xu, G. Varga, D. E. Zinn Jr., C. Crabbs, W. Wagner, J. Greenhouse, P. Silvera, J. Yalley-Ogunro, et al. (2000)
Science 290, 1591-1593
   Abstract »    Full Text »
Efficacy of Postexposure Prophylaxis after Intravaginal Exposure of Pig-Tailed Macaques to a Human-Derived Retrovirus (Human Immunodeficiency Virus Type 2).
R. A. Otten, D. K. Smith, D. R. Adams, J. K. Pullium, E. Jackson, C. N. Kim, H. Jaffe, R. Janssen, S. Butera, and T. M. Folks (2000)
J. Virol. 74, 9771-9775
   Abstract »    Full Text »    PDF »
Failure To Develop HIV Infection after Receipt of HIV-Contaminated Blood and Postexposure Prophylaxis.
T. L. Katzenstein, E. Dickmeiss, H. Aladdin, A. Hede, C. Nielsen, H. Nielsen, L. B. Jorgensen, and J. Gerstoft (2000)
Ann Intern Med 133, 31-34
   Abstract »    Full Text »    PDF »
Suppression of Acute Viremia by Short-Term Postexposure Prophylaxis of Simian/Human Immunodeficiency Virus SHIV-RT-Infected Monkeys with a Novel Reverse Transcriptase Inhibitor (GW420867) Allows for Development of Potent Antiviral Immune Responses Resulting in Efficient Containment of Infection.
K. Mori, Y. Yasutomi, S. Sawada, F. Villinger, K. Sugama, B. Rosenwith, J. L. Heeney, K. Uberla, S. Yamazaki, A. A. Ansari, et al. (2000)
J. Virol. 74, 5747-5753
   Abstract »    Full Text »    PDF »
Antiretroviral Therapy during Primary Immunodeficiency Virus Infection Can Induce Persistent Suppression of Virus Load and Protection from Heterologous Challenge in Rhesus Macaques.
B. Rosenwirth, P. ten Haaft, W. M. J. M. Bogers, I. G. Nieuwenhuis, H. Niphuis, E.-M. Kuhn, N. Bischofberger, J. L. Heeney, and K. Uberla (2000)
J. Virol. 74, 1704-1711
   Abstract »    Full Text »    PDF »
Prophylactic and Therapeutic Benefits of Short-Term 9-[2-(R)-(Phosphonomethoxy)Propyl]Adenine (PMPA) Administration to Newborn Macaques following Oral Inoculation with Simian Immunodeficiency Virus with Reduced Susceptibility to PMPA.
K. K. A. Van Rompay, M. D. Miller, M. L. Marthas, N. A. Margot, P. J. Dailey, D. R. Canfield, R. P. Tarara, J. M. Cherrington, N. L. Aguirre, N. Bischofberger, et al. (2000)
J. Virol. 74, 1767-1774
   Abstract »    Full Text »    PDF »
Postinoculation PMPA Treatment, but Not Preinoculation Immunomodulatory Therapy, Protects against Development of Acute Disease Induced by the Unique Simian Immunodeficiency Virus SIVsmmPBj.
S. Hodge, J. de Rosayro, A. Glenn, I. C. Ojukwu, S. Dewhurst, H. M. McClure, N. Bischofberger, D. C. Anderson, S. A. Klumpp, and F. J. Novembre (1999)
J. Virol. 73, 8630-8639
   Abstract »    Full Text »    PDF »
Antiretroviral-Drug Concentrations in Semen: Implications for Sexual Transmission of Human Immunodeficiency Virus Type 1.
A. D. M. Kashuba, J. R. Dyer, L. M. Kramer, R. H. Raasch, J. J. Eron, and M. S. Cohen (1999)
Antimicrob. Agents Chemother. 43, 1817-1826
   Full Text »    PDF »
Activated Memory CD4+ T Helper Cells Repopulate the Intestine Early following Antiretroviral Therapy of Simian Immunodeficiency Virus-Infected Rhesus Macaques but Exhibit a Decreased Potential To Produce Interleukin-2.
J. J. Mattapallil, Z. Smit-McBride, P. Dailey, and S. Dandekar (1999)
J. Virol. 73, 6661-6669
   Abstract »    Full Text »    PDF »
Simian Immunodeficiency Virus Disease Course Is Predicted by the Extent of Virus Replication during Primary Infection.
S. I. Staprans, P. J. Dailey, A. Rosenthal, C. Horton, R. M. Grant, N. Lerche, and M. B. Feinberg (1999)
J. Virol. 73, 4829-4839
   Abstract »    Full Text »    PDF »
9-[2-(Phosphonomethoxy)propyl]adenine (PMPA) Therapy Prolongs Survival of Infant Macaques Inoculated with Simian Immunodeficiency Virus with Reduced Susceptibility to PMPA.
K. K. A. van Rompay, J. M. Cherrington, M. L. Marthas, P. D. Lamy, P. J. Dailey, D. R. Canfield, R. P. Tarara, N. Bischofberger, and N. C. Pedersen (1999)
Antimicrob. Agents Chemother. 43, 802-812
   Abstract »    Full Text »    PDF »
Early Short-Term 9-[2-(R)-(Phosphonomethoxy)Propyl]Adenine Treatment Favorably Alters the Subsequent Disease Course in Simian Immunodeficiency Virus-Infected Newborn Rhesus Macaques.
K. K. A. van Rompay, P. J. Dailey, R. P. Tarara, D. R. Canfield, N. L. Aguirre, J. M. Cherrington, P. D. Lamy, N. Bischofberger, N. C. Pedersen, and M. L. Marthas (1999)
J. Virol. 73, 2947-2955
   Abstract »    Full Text »    PDF »
Postexposure Chemoprophylaxis for Occupational Exposures to the Human Immunodeficiency Virus.
D. K. Henderson (1999)
JAMA 281, 931-936
   Full Text »    PDF »
Early physiological abnormalities after simian immunodeficiency virus infection.
T. F. W. Horn, S. Huitron-Resendiz, M. R. Weed, S. J. Henriksen, and H. S. Fox (1998)
PNAS 95, 15072-15077
   Abstract »    Full Text »    PDF »
Postexposure Prophylaxis After Nonoccupational HIV Exposure: Clinical, Ethical, and Policy Considerations.
P. Lurie, S. Miller, F. Hecht, M. Chesney, and B. Lo (1998)
JAMA 280, 1769-1773
   Abstract »    Full Text »    PDF »
Abbreviated Regimens of Zidovudine Prophylaxis and Perinatal Transmission of the Human Immunodeficiency Virus.
N. A. Wade, G. S. Birkhead, B. L. Warren, T. T. Charbonneau, P. T. French, L. Wang, J. B. Baum, J. M. Tesoriero, and R. Savicki (1998)
N. Engl. J. Med. 339, 1409-1414
   Abstract »    Full Text »    PDF »
Selective Inhibition of HIV-1 Reverse Transcriptase by an Antiviral Inhibitor, (R)-9-(2-Phosphonylmethoxypropyl)adenine.
Z. Suo and K. A. Johnson (1998)
J. Biol. Chem. 273, 27250-27258
   Abstract »    Full Text »    PDF »
Safety, Pharmacokinetics, and Antiretroviral Activity of Intravenous 9-[2-(R)-(Phosphonomethoxy)propyl]adenine, a Novel Anti-Human Immunodeficiency Virus (HIV) Therapy, in HIV-Infected Adults.
S. G. Deeks, P. Barditch-Crovo, P. S. Lietman, F. Hwang, K. C. Cundy, J. F. Rooney, N. S. Hellmann, S. Safrin, and J. O. Kahn (1998)
Antimicrob. Agents Chemother. 42, 2380-2384
   Abstract »    Full Text »    PDF »
Antiretroviral Efficacy and Pharmacokinetics of Oral Bis(isopropyloxycarbonyloxymethyl)9-(2-Phosphonylmethoxypropyl)adenine in Mice.
L. Naesens, N. Bischofberger, P. Augustijns, P. Annaert, G. Van den Mooter, M. N. Arimilli, C. U. Kim, and E. De Clercq (1998)
Antimicrob. Agents Chemother. 42, 1568-1573
   Abstract »    Full Text »    PDF »
Antiviral Activities of 9-R-2-Phosphonomethoxypropyl Adenine (PMPA) and Bis(isopropyloxymethylcarbonyl)PMPA against Various Drug-Resistant Human Immunodeficiency Virus Strains.
R. V. Srinivas and A. Fridland (1998)
Antimicrob. Agents Chemother. 42, 1484-1487
   Abstract »    Full Text »    PDF »
Effectiveness of Postinoculation (R)-9-(2-Phosphonylmethoxypropyl)Adenine Treatment for Prevention of Persistent Simian Immunodeficiency Virus SIVmne Infection Depends Critically on Timing of Initiation and Duration of Treatment.
C.-C. Tsai, P. Emau, K. E. Follis, T. W. Beck, R. E. Benveniste, N. Bischofberger, J. D. Lifson, and W. R. Morton (1998)
J. Virol. 72, 4265-4273
   Abstract »    Full Text »    PDF »
Anti-Human Immunodeficiency Virus Activity and Cellular Metabolism of a Potential Prodrug of the Acyclic Nucleoside Phosphonate 9-R-(2-Phosphonomethoxypropyl)adenine (PMPA), Bis(isopropyloxymethylcarbonyl)PMPA.
B. L. Robbins, R. V. Srinivas, C. Kim, N. Bischofberger, and A. Fridland (1998)
Antimicrob. Agents Chemother. 42, 612-617
   Abstract »    Full Text »    PDF »
Pharmacokinetics and Bioavailability of the Anti-Human Immunodeficiency Virus Nucleotide Analog 9-[(R)2-(Phosphonomethoxy)Propyl]Adenine (PMPA) in Dogs.
K. C. Cundy, C. Sueoka, G. R. Lynch, L. Griffin, W. A. Lee, and J.-P. Shaw (1998)
Antimicrob. Agents Chemother. 42, 687-690
   Abstract »    Full Text »    PDF »
A Case-Control Study of HIV Seroconversion in Health Care Workers after Percutaneous Exposure.
D. M. Cardo, D. H. Culver, C. A. Ciesielski, P. U. Srivastava, R. Marcus, D. Abiteboul, J. Heptonstall, G. Ippolito, F. Lot, P. S. McKibben, et al. (1997)
N. Engl. J. Med. 337, 1485-1490
   Abstract »    Full Text »    PDF »
Postexposure Treatment of HIV -- Taking Some Risks for Safety's Sake.
D. K. Henderson (1997)
N. Engl. J. Med. 337, 1542-1543
   Full Text »
Intracellular Metabolism and Action of Acyclic Nucleoside Phosphonates on DNA Replication.
V. M. Pisarev, S.-H. Lee, M. C. Connelly, and A. Fridland (1997)
Mol. Pharmacol. 52, 63-68
   Abstract »    Full Text »
Toxicity of Antiviral Nucleoside Analogs and the Human Mitochondrial DNA Polymerase.
A. A. Johnson, A. S. Ray, J. Hanes, Z. Suo, J. M. Colacino, K. S. Anderson, and K. A. Johnson (2001)
J. Biol. Chem. 276, 40847-40857
   Abstract »    Full Text »    PDF »
Macrophage are the principal reservoir and sustain high virus loads in rhesus macaques after the depletion of CD4+ T cells by a highly pathogenic simian immunodeficiency virus/HIV type 1 chimera (SHIV): Implications for HIV-1 infections of humans.
T. Igarashi, C. R. Brown, Y. Endo, A. Buckler-White, R. Plishka, N. Bischofberger, V. Hirsch, and M. A. Martin (2001)
PNAS 98, 658-663
   Abstract »    Full Text »    PDF »


To Advertise     Find Products

Science. ISSN 0036-8075 (print), 1095-9203 (online)